Feb 27, 2020 / 02:00PM GMT
Danielle Joy Antalffy - SVB Leerink LLC, Research Division - MD of Medical Supplies & Devices and Senior Analyst
Okay. Good morning, everyone. Thank you so much for joining us. My name is Danielle Antalffy. I'm one of the senior medtech analysts here at SVB Leerink, and we are very lucky to have with us Insulet management team. We have CFO, Wayde McMillan; and we have CCO, Bret Christensen. We also have Deb Gordon, Head of Investor Relations in the audience there. We're just going to launch into Q&A. This is a fireside chat format. If you have any questions, feel free to raise your hand, and we'll get a mic to you. So guys and gals thanks for joining us.
Questions and Answers:
Danielle Joy Antalffy - SVB Leerink LLC, Research Division - MD of Medical Supplies & Devices and Senior AnalystWhy don't we start. You guys did just report earnings, Q4 earnings on Tuesday night, and you did issue guidance of 14% to 18% for 2020. And I think one of the questions I've been getting as it relates to guidance is sort of it feels conservative. Just trying to
Trustpilot
